KalVista Pharmaceuticals (KALV) Exchange Rate Effect (2016 - 2025)
KalVista Pharmaceuticals (KALV) reported Exchange Rate Effect of $2.7 million for Q3 2025, up 2227.35% on a YoY basis from $117000.0 in Q3 2024, and down 19.05% sequentially from $3.4 million in Q2 2025.
KalVista Pharmaceuticals (KALV) Exchange Rate Effect (2016 - 2025) Analysis & Trends
KalVista Pharmaceuticals (KALV) has 10 years of Exchange Rate Effect data on file, last reported at $2.7 million in Q3 2025.
- For the quarter ending Q3 2025, Exchange Rate Effect rose 2227.35% year-over-year to $2.7 million; the trailing twelve-month figure through Jul 2025 stood at $6.6 million (up 660.25% YoY), and the FY2025 full-year result was $2.6 million, up 317.56% from the prior year.
- Exchange Rate Effect retreated to $2.7 million in Q3 2025, from $3.4 million in the prior quarter.
- In the past five years, Exchange Rate Effect ranged from a high of $3.4 million in Q2 2025 to a low of -$628000.0 in Q2 2022.
- A 5-year average of $335722.2 and a median of $76000.0 in 2023 frame the typical range for Exchange Rate Effect.
- Peak annual rise in Exchange Rate Effect reached 8176.92% in 2022, while the deepest fall reached 11200.0% in 2022.
- Tracing KALV's Exchange Rate Effect over 5 years: stood at -$13000.0 in 2021, then soared by 8176.92% to $1.0 million in 2022, then plunged by 157.33% to -$602000.0 in 2023, then jumped by 167.61% to $407000.0 in 2024, then soared by 569.04% to $2.7 million in 2025.
- Business Quant data shows KALV's Exchange Rate Effect at $2.7 million in Q3 2025, $3.4 million in Q2 2025, and $407000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 619,347.27 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 19.32 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 14,631.83 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -40.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -900,000.00 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | KalVista Pharmaceuticals | 1.36 Bn | 1.36 Bn | 49.41 Mn | 2.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 2.72 Mn |
| Jul 31, 2025 | 2.72 Mn |
| Apr 30, 2025 | 3.36 Mn |
| Apr 30, 2025 | 3.36 Mn |
| Oct 31, 2024 | 407,000.00 |
| Oct 31, 2024 | 407,000.00 |
| Jul 31, 2024 | 117,000.00 |
| Jul 31, 2024 | 117,000.00 |
| Apr 30, 2024 | -74,000.00 |
| Apr 30, 2024 | -74,000.00 |
| Jan 31, 2024 | -621,000.00 |
| Jan 31, 2024 | -621,000.00 |
| Oct 31, 2023 | -602,000.00 |
| Oct 31, 2023 | -602,000.00 |
| Jul 31, 2023 | 84,000.00 |
| Jul 31, 2023 | 84,000.00 |
| Apr 30, 2023 | 68,000.00 |
| Apr 30, 2023 | 68,000.00 |
| Jan 31, 2023 | 457,000.00 |
| Jan 31, 2023 | 457,000.00 |